Meanwhile, adoption of existing medications for SUD is very low, particularly for AUD: AUD is a leading cause of mortality and morbidity, but compared with other chronic diseases such as cancers, hypertension, diabetes and depression, there is a very small number of US Food and Drug administration (FDA)-approved medications for AUD (acamprosate, disulfiram and naltrexone)
Its taken once a week and was approved by the FDA in 2017 to treat type 2 diabetes
How GLP-1 Receptor Agonists May Modulate Stress Hormone Pathways GLP-1 receptors exist not only in the pancreas and gastrointestinal tract but also in regions of the brain involved in stress perception and emotion regulation, including the hypothalamus and amygdala
Many plans report that GLP-1s now represent one of their top three pharmacy spend categories, with costs driven by: expanding FDA indications increased off-label use long-term or indefinite treatment duration high rates of discontinuation followed by weight regain These pressures are pushing employers to adopt a more strategic approach: covering GLP-1s when clinically appropriate, while pairing them with programs that address nutrition, activity, sleep, and behavioral health
Consider work-from-home options: If your job allows flexibility, working from home during the first few days after dose increases may reduce stress
